{"id":"https://openalex.org/W3120541246","doi":"https://doi.org/10.1007/s00262-020-02833-z","title":"Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients","display_name":"Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients","publication_year":2021,"publication_date":"2021-01-09","ids":{"openalex":"https://openalex.org/W3120541246","doi":"https://doi.org/10.1007/s00262-020-02833-z","mag":"3120541246","pmid":"https://pubmed.ncbi.nlm.nih.gov/33420629","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8195930"},"language":"en","primary_location":{"id":"doi:10.1007/s00262-020-02833-z","doi":"https://doi.org/10.1007/s00262-020-02833-z","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00262-020-02833-z","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00262-020-02833-z.pdf","source":{"id":"https://openalex.org/S203303425","display_name":"Cancer Immunology Immunotherapy","issn_l":"0340-7004","issn":["0340-7004","1432-0851"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Immunology, Immunotherapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s00262-020-02833-z.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053902910","display_name":"Elliot Naidus","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I4210124134","display_name":"Mills Peninsula Health Services","ror":"https://ror.org/02vnyaz83","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I114073160","https://openalex.org/I4210124134"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elliot Naidus","raw_affiliation_strings":["Department of Medicine, Mills-Peninsula Medical Center, Burlingame, CA, USA","Department of Medicine, University of California San Francisco, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Mills-Peninsula Medical Center, Burlingame, CA, USA","institution_ids":["https://openalex.org/I4210124134"]},{"raw_affiliation_string":"Department of Medicine, University of California San Francisco, San Francisco, CA, USA","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012976869","display_name":"J\u00e9r\u00f4me Bouquet","orcid":"https://orcid.org/0000-0001-8077-6025","observed_orcids":["https://orcid.org/0000-0001-8077-6025"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jerome Bouquet","raw_affiliation_strings":["Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058893054","display_name":"David Yoonsuk Oh","orcid":"https://orcid.org/0000-0002-3310-0994","observed_orcids":["https://orcid.org/0000-0002-3310-0994"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I4210167126","display_name":"UCSF Helen Diller Family Comprehensive Cancer Center","ror":"https://ror.org/05yndxy10","country_code":"US","type":"facility","lineage":["https://openalex.org/I180670191","https://openalex.org/I4210110664","https://openalex.org/I4210167126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Y. Oh","raw_affiliation_strings":["Department of Medicine, University of California San Francisco, San Francisco, CA, USA","Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, University of California San Francisco, San Francisco, CA, USA","institution_ids":["https://openalex.org/I180670191"]},{"raw_affiliation_string":"Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210167126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042832211","display_name":"Timothy J. Looney","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142480","display_name":"Thermo Fisher Scientific (United States)","ror":"https://ror.org/03x1ewr52","country_code":"US","type":"company","lineage":["https://openalex.org/I4210142480"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Timothy J. Looney","raw_affiliation_strings":["Thermo Fisher Scientific, Austin, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Thermo Fisher Scientific, Austin, TX, USA","institution_ids":["https://openalex.org/I4210142480"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Hai Yang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I4210167126","display_name":"UCSF Helen Diller Family Comprehensive Cancer Center","ror":"https://ror.org/05yndxy10","country_code":"US","type":"facility","lineage":["https://openalex.org/I180670191","https://openalex.org/I4210110664","https://openalex.org/I4210167126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hai Yang","raw_affiliation_strings":["Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210167126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073970384","display_name":"Lawrence H. Fong","orcid":"https://orcid.org/0000-0002-6428-428X","observed_orcids":["https://orcid.org/0000-0002-6428-428X"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I4210167126","display_name":"UCSF Helen Diller Family Comprehensive Cancer Center","ror":"https://ror.org/05yndxy10","country_code":"US","type":"facility","lineage":["https://openalex.org/I180670191","https://openalex.org/I4210110664","https://openalex.org/I4210167126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lawrence Fong","raw_affiliation_strings":["Department of Medicine, University of California San Francisco, San Francisco, CA, USA","Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, University of California San Francisco, San Francisco, CA, USA","institution_ids":["https://openalex.org/I180670191"]},{"raw_affiliation_string":"Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210167126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080517610","display_name":"Nathan E. Standifer","orcid":"https://orcid.org/0000-0002-9328-1889","observed_orcids":["https://orcid.org/0000-0002-9328-1889"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Nathan E. Standifer","raw_affiliation_strings":["Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA, USA. nathan.standifer@astrazeneca.com","Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA, USA. nathan.standifer@astrazeneca.com","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100425554","display_name":"Li Zhang","orcid":"https://orcid.org/0000-0002-3617-2627","observed_orcids":["https://orcid.org/0000-0002-3617-2627","https://orcid.org/0000-0003-2756-2620","https://orcid.org/0009-0001-8129-4308"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I4210167126","display_name":"UCSF Helen Diller Family Comprehensive Cancer Center","ror":"https://ror.org/05yndxy10","country_code":"US","type":"facility","lineage":["https://openalex.org/I180670191","https://openalex.org/I4210110664","https://openalex.org/I4210167126"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Li Zhang","raw_affiliation_strings":["Department of Epidemiology Biostatistics, University of California San Francisco, 550 16th Street, Room 6708, UCSF, Box 3211, San Francisco, CA, 94158, USA. li.zhang@ucsf.edu","Department of Medicine, University of California San Francisco, San Francisco, CA, USA. li.zhang@ucsf.edu","Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. li.zhang@ucsf.edu","Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA"],"raw_orcid":"https://orcid.org/0000-0002-3617-2627","affiliations":[{"raw_affiliation_string":"Department of Epidemiology Biostatistics, University of California San Francisco, 550 16th Street, Room 6708, UCSF, Box 3211, San Francisco, CA, 94158, USA. li.zhang@ucsf.edu","institution_ids":["https://openalex.org/I180670191"]},{"raw_affiliation_string":"Department of Medicine, University of California San Francisco, San Francisco, CA, USA. li.zhang@ucsf.edu","institution_ids":["https://openalex.org/I180670191"]},{"raw_affiliation_string":"Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. li.zhang@ucsf.edu","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210167126"]},{"raw_affiliation_string":"Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210167126"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5080517610","https://openalex.org/A5100425554"],"corresponding_institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210150756","https://openalex.org/I4210167126"],"apc_list":{"value":3860,"currency":"USD","value_usd":3860},"apc_paid":{"value":3860,"currency":"USD","value_usd":3860},"fwci":2.0928,"has_fulltext":true,"cited_by_count":28,"citation_normalized_percentile":{"value":0.9076514,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":99},"biblio":{"volume":"70","issue":"7","first_page":"2095","last_page":"2102"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/durvalumab","display_name":"durvalumab","score":1.0},{"id":"https://openalex.org/keywords/pd-l1-blockade","display_name":"PD-L1 blockade","score":0.9929999709129333},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9599999785423279},{"id":"https://openalex.org/keywords/tcr-repertoire","display_name":"T cell receptor repertoire","score":0.8019999861717224},{"id":"https://openalex.org/keywords/tcr-diversity","display_name":"TCR diversity","score":0.8029999732971191},{"id":"https://openalex.org/keywords/peripheral-blood-t-cells","display_name":"peripheral blood T cells","score":0.8080000281333923},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.734000027179718},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.871999979019165},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8529999852180481},{"id":"https://openalex.org/keywords/t-cell-clonotypes","display_name":"T cell clonotypes","score":0.8960000276565552},{"id":"https://openalex.org/keywords/t-cell-exhaustion","display_name":"T cell exhaustion","score":0.6309999823570251},{"id":"https://openalex.org/keywords/pharmacodynamic-activity","display_name":"pharmacodynamic activity","score":0.4230000078678131}],"concepts":[{"id":"https://openalex.org/C2777742743","wikidata":"https://www.wikidata.org/wiki/Q19904005","display_name":"Durvalumab","level":5,"score":0.9784688949584961},{"id":"https://openalex.org/C19317047","wikidata":"https://www.wikidata.org/wiki/Q412037","display_name":"T-cell receptor","level":4,"score":0.5855534672737122},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5563463568687439},{"id":"https://openalex.org/C2778650287","wikidata":"https://www.wikidata.org/wiki/Q7838098","display_name":"Tremelimumab","level":5,"score":0.5382305383682251},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5188809037208557},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4948734641075134},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.47625064849853516},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.46716463565826416},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.44931310415267944},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.43396201729774475},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39905670285224915},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.384605348110199},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.23345130681991577},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.06641733646392822},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.0}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011948","descriptor_name":"Receptors, Antigen, T-Cell","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D011948","descriptor_name":"Receptors, Antigen, T-Cell","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060890","descriptor_name":"B7-H1 Antigen","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1007/s00262-020-02833-z","doi":"https://doi.org/10.1007/s00262-020-02833-z","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00262-020-02833-z","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00262-020-02833-z.pdf","source":{"id":"https://openalex.org/S203303425","display_name":"Cancer Immunology Immunotherapy","issn_l":"0340-7004","issn":["0340-7004","1432-0851"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Immunology, Immunotherapy","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8195930","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8195930","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Immunol Immunother","raw_type":"Text"},{"id":"pmid:33420629","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33420629","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer immunology, immunotherapy : CII","raw_type":"Journal Article"},{"id":"pmh:oai:escholarship.org:ark:/13030/qt53t0g7b0","doi":null,"is_oa":true,"landing_page_url":"https://escholarship.org/uc/item/53t0g7b0","pdf_url":null,"source":{"id":"https://openalex.org/S4306400115","display_name":"eScholarship (California Digital Library)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2801248553","host_organization_name":"California Digital Library","host_organization_lineage":["https://openalex.org/I2801248553"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Cancer Immunology, Immunotherapy, vol 70, iss 7","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1007/s00262-020-02833-z","doi":"https://doi.org/10.1007/s00262-020-02833-z","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00262-020-02833-z","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00262-020-02833-z.pdf","source":{"id":"https://openalex.org/S203303425","display_name":"Cancer Immunology Immunotherapy","issn_l":"0340-7004","issn":["0340-7004","1432-0851"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Immunology, Immunotherapy","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[{"id":"https://openalex.org/G188316834","display_name":"Determinants of prostate cancer sensitivity to PD-1 blockade","funder_award_id":"R01CA223484","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G7240243037","display_name":"Molecular and immune drivers of immunotherapy responsiveness in prostate cancer","funder_award_id":"U01CA233100","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G7491532527","display_name":"Molecular Pathology of Cancer","funder_award_id":"T32CA177555","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G8650473052","display_name":"Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events","funder_award_id":"K08AI139375","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"}],"funders":[{"id":"https://openalex.org/F4320306163","display_name":"Prostate Cancer Foundation","ror":"https://ror.org/01npwtv09"},{"id":"https://openalex.org/F4320306239","display_name":"Conquer Cancer Foundation","ror":"https://ror.org/027327e78"},{"id":"https://openalex.org/F4320311529","display_name":"Bladder Cancer Advocacy Network","ror":"https://ror.org/04p3pep55"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"},{"id":"https://openalex.org/F4320337355","display_name":"National Institute of Allergy and Infectious Diseases","ror":"https://ror.org/043z4tv69"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3120541246.pdf","grobid_xml":"https://content.openalex.org/works/W3120541246.grobid-xml"},"referenced_works_count":23,"referenced_works":["https://openalex.org/W2039123767","https://openalex.org/W2156353875","https://openalex.org/W2198093519","https://openalex.org/W2293828571","https://openalex.org/W2296947286","https://openalex.org/W2527905628","https://openalex.org/W2560830801","https://openalex.org/W2591007377","https://openalex.org/W2605630275","https://openalex.org/W2609289346","https://openalex.org/W2753065806","https://openalex.org/W2797855256","https://openalex.org/W2867818201","https://openalex.org/W2900501647","https://openalex.org/W2901601525","https://openalex.org/W2924247059","https://openalex.org/W2947183331","https://openalex.org/W2971124518","https://openalex.org/W2985693568","https://openalex.org/W2997606761","https://openalex.org/W2998886190","https://openalex.org/W3088579092","https://openalex.org/W3115055915"],"related_works":["https://openalex.org/W3029948034","https://openalex.org/W4393090396","https://openalex.org/W3137239260","https://openalex.org/W2985693568","https://openalex.org/W4406382316","https://openalex.org/W4407902852","https://openalex.org/W7161408946","https://openalex.org/W7162439122","https://openalex.org/W4379340635","https://openalex.org/W2981445350"],"abstract_inverted_index":{"Immune":[0],"checkpoint":[1],"inhibitors":[2],"(ICI)":[3],"are":[4],"designed":[5],"to":[6,14,22,134,170],"activate":[7],"exhausted":[8],"tumor-reactive":[9],"T":[10,64,85,173],"cells":[11,53,65,86],"thereby":[12],"leading":[13],"tumor":[15],"regression.":[16],"Durvalumab,":[17],"an":[18,178],"ICI":[19],"that":[20],"binds":[21],"the":[23,83,135],"programmed":[24],"death":[25],"ligand-1":[26],"(PD-L1)":[27],"molecule,":[28],"is":[29],"approved":[30],"as":[31],"a":[32,99,224],"consolidation":[33],"therapy":[34,213],"for":[35,158,198,214,227],"treatment":[36],"of":[37,50,74,91,109,177,219],"patients":[38,94,137,199],"with":[39,160,183,200],"stage":[40],"III,":[41],"unresectable,":[42],"non-small":[43],"cell":[44,174],"lung":[45],"cancer":[46],"(NSCLC).":[47],"Immunophenotypic":[48],"analysis":[49,169],"circulating":[51,57,84],"immune":[52,180],"revealed":[54],"increases":[55],"in":[56,98],"proliferating":[58],"CD4":[59],"+":[60,63],"and":[61,76,88,123,222],"CD8":[62],"earlier":[66],"after":[67,211],"durvalumab":[68,96,212,228],"treatment.":[69],"To":[70],"examine":[71],"durvalumab's":[72],"mechanism":[73],"action":[75],"identify":[77],"potential":[78],"predictive":[79,218],"biomarkers,":[80],"we":[81],"assessed":[82],"phenotypes":[87],"TCR":[89,110,128,185,202,208],"genes":[90],"71":[92],"NSCLC":[93,116,215],"receiving":[95],"enrolled":[97],"Phase":[100],"I":[101],"trial":[102],"(NCT01693562,":[103],"September":[104],"14,":[105],"2012).":[106],"Next-generation":[107],"sequencing":[108],"repertoire":[111,129,209],"was":[112,152,192],"performed":[113],"on":[114,141],"these":[115],"patients'":[117,127],"peripheral":[118],"blood":[119],"samples":[120],"at":[121],"baseline":[122],"day":[124,142],"15.":[125],"Though":[126],"diversity":[130,140],"showed":[131],"mixed":[132],"responses":[133],"treatment,":[136],"exhibiting":[138],"increased":[139,220],"15":[143],"attained":[144],"significantly":[145],"longer":[146],"overall":[147],"survival":[148,221],"(OS)":[149],"(median":[150,190],"OS":[151,189,191],"not":[153,193],"reached":[154,194],"vs":[155,195],"17.2":[156],"months":[157,197],"those":[159],"decreased":[161],"diversity,":[162],"p":[163,204],"=":[164,205],"0.015).":[165],"We":[166],"applied":[167],"network":[168],"assess":[171],"convergent":[172],"clonotypes":[175],"indicative":[176],"antigen-driven":[179],"response.":[181],"Patients":[182],"larger":[184],"clusters":[186],"had":[187],"improved":[188],"13.1":[196],"smaller":[201],"clusters,":[203],"0.013).":[206],"Early":[207],"diversification":[210],"may":[216],"be":[217],"provides":[223],"mechanistic":[225],"basis":[226],"pharmacodynamic":[229],"activity.":[230]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":4}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2021-01-18T00:00:00"}